clinical trial · NCT02584933
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
ALK Positive Malignanciesceritinib
brief summary
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
started
Dec 11, 2015
primary completion
Jun 9, 2027
completion
Jun 9, 2027
last updated
Apr 2, 2026
official title
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol